Bisphosphonates-What the Dentist Needs to Know: Practical Considerations

Journal of Oral and Maxillofacial Surgery

Volumn 67, Issue 5 SUPPL., 2009, Pages 53-60

  Fantasia, John E ^a  

^a North Shore Long Island Jewish Health System ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE TURNOVER; DENTAL CARE; DENTIST; DRUG WITHDRAWAL; ELECTIVE SURGERY; HUMAN; INCIDENCE; JAW OSTEONECROSIS; ORAL SURGERY; PREVENTIVE DENTISTRY; RISK BENEFIT ANALYSIS;

AGED; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE REMODELING; COLLAGEN TYPE I; DENTAL CARE FOR CHRONICALLY ILL; DENTAL IMPLANTATION, ENDOSSEOUS; DIPHOSPHONATES; FEMALE; GLUCOCORTICOIDS; HUMANS; JAW DISEASES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NITROGEN; OSTEONECROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; PHOSPHORUS; TOOTH EXTRACTION;

EID: 64249114477     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2009.01.011     Document Type: Article

References (38)

1. Mehrotra B., Fantasia J., Nissel-Horowitz S., et al. Osteonecrosis of the maxilla: An unusual complication of prolonged bisphosphonate therapy: A case report. Proc Am Soc Clin Oncol 22 (2003) 795
2. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527
3. Ruggiero S.L., and Drew S.J. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 86 (2007) 1013
4. Kimmel D.B. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86 (2007) 1022
5. Sarasquete M.E., Garcia-Sanz R., Marin L., et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis. Blood 112 (2008) 2709
6. Scheper MA, Baros A, Chaisuparat R, et al: Effect of zoledronic acid on oral fibroblasts and epithelial cells: A potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol Epub 2008 Nov 27
7. Landesberg R., Cozin M., Cremers S., et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66 (2008) 839
8. Hellstein J.W. Bisphosphonate induced osteochemonecrosis of the jaws: An ounce of prevention may be worth a pound of cure. Spec Care Dentistry 26 (2006) 8
9. Lerner U.H. Bone remodeling in post-menopausal osteoporosis. J Dent Res 85 (2006) 584
10. Saag K., Lindsay R., Kreigman A., et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 40 (2007) 1238
11. Hillner B.E., Ingle J.N., Berenson J.R., et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18 (2000) 1378
12. Chen T., Berenson J., Vescio R., et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42 (2002) 1228
13. Raje N., Woo S.B., Hande K., et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res 14 (2008) 2387
14. Berenson J.R., Yellin O., Boccia R.V., et al. Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss. Clin Cancer Res 14 (2008) 6289
15. Santini D., Vincenzi B., Hannon R.A., et al. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncol Reports 15 (2006) 1351
16. Gleeson H., Wiltshire E., Briody J., et al. Childhood chronic recurrent multifocal osteomyelitis: Pamidronate therapy decreases pain and improves vertebral shape. J Rheumatol 35 (2008) 707
17. Gibbons C.L.M.H., Petra M., Smith R., et al. Bisphosphonate treatment of benign multifocal and unifocal osteolytic tumours of bone. Sarcoma 7 (2003) 35
18. Cartos V.M., Zhu S., and Zavras A. Bisphosphonate use and the risk of adverse jaw outcomes: A medical claims study of 714,217 people. J Am Dent Assoc 139 (2008) 23
19. Grbic J.T., Landesberg R., Lin S.Q., et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial. J Am Dent Assoc 139 (2008) 32
20. Carey J.J., and Palomo L. Bisphosphonates and osteonecrosis of the jaw: Innocent association or significant risk?. Cleveland Clinic J Med 75 (2008) 871
21. Miller P.D., Bolognese M.A., Lewiecki E.M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone 43 (2008) 222
22. Woo S.B., Hellstein J.W., and Kalmar J.R. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753
23. Ruggiero S.L., Fantasia J., and Carlson E. Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 (2006) 433
24. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 (2007) 369
25. Polizzotto M.N., Cousins V., and Schwarer A.P. Bisphosphonate-associated osteonecrosis of the auditory canal. Br J Haematol 132 (2006) 114
26. Marx R.E., Cillo J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65 (2007) 2397
27. Sedghizadeh P.P., Kumar S.K.S., Gorur A., et al. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 66 (2008) 767
28. Christgau S., and Cloos P.A.C. Current and future applications of bone turnover markers. Clin Lab 49 (2003) 439
29. Bolland M.J., Grey A.B., Horne A.M., et al. Effects of intravenous zoledronate on bone turnover and BMD persists for at least 24 months. J Bone Miner Res 23 (2008) 1304
30. Generali D., Dovio A., and Tampellini M. Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. Br J Cancer 98 (2008) 1753
31. Lehrer S., Montazem A., Ramanathan L., et al. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106 (2008) 389
32. Alexandersen P., Peris P., Guañabens N., et al. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. J Bone Miner Res 20 (2005) 588
33. Chan K.C., and Fantasia J. Oral bisphosphonates and jaw osteonecrosis: Preliminary results of a single institution, retrospective analysis. Joint Meeting of the International Association of Oral Pathologists and American Academy of Oral and Maxillofacial Pathology, San Francisco (June 2008) AAOMP abstract 174
34. Edwards B.J., Hellstein J.W., Jacobsen P.L., et al. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisor statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 139 (2008) 1674
35. Sedghizadeh P.P., Stanley B.S., Caligiuri M., et al. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw. J Am Dent Assoc 140 (2009) 61
36. Hellstein J.W., and Marek C.L. Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century?. J Oral Maxillofac Surg 63 (2005) 682
37. Donaghue A.M. Bisphosphonates and osteonecrosis: Analogy to phossy jaw. Med J Aust 183 (2005) 163
38. Marx R.E. Uncovering the cause of "phossy jaw" circa 1858 to 1906: Oral and maxillofacial surgery closed case file-Case closed. J Oral Maxillofac Surg 66 (2008) 2356